Related Experiment Video

Updated: Nov 6, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K

Biochanin A Mitigates Atherosclerosis by Inhibiting Lipid Accumulation and Inflammatory Response

Xiao-Hua Yu1, Jiao-Jiao Chen1, Wen-Yi Deng1

  • 1Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570100 Hainan, China.

Oxidative Medicine and Cellular Longevity
|May 7, 2021
PubMed

Insights

Biochanin A (BCA) combats atherosclerosis by enhancing cholesterol removal and reducing inflammation. This dietary compound activates key pathways, offering potential for treating cardiovascular disease.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Nutritional Science

Background:

  • Atherosclerosis is a complex disease driven by lipid accumulation and inflammation.
  • Biochanin A (BCA), a red clover isoflavone, has known cardiovascular benefits but its role in atherogenesis is unclear.

Purpose of the Study:

  • To investigate the effects of Biochanin A on atherosclerosis.
  • To elucidate the underlying molecular mechanisms of BCA's action in atherogenesis.

Main Methods:

  • Administration of BCA to apoE-/- mice on a Western diet.
  • Analysis of plasma lipid profiles, inflammatory cytokines, and atherosclerotic lesion area.
  • In vitro studies using THP-1 macrophage-derived foam cells to assess cholesterol efflux and signaling pathways.

Main Results:

  • BCA administration improved lipid profiles, promoted reverse cholesterol transport (RCT), and reduced atherosclerotic lesions in mice.
  • BCA upregulated ABCA1 and ABCG1 expression in foam cells, facilitating cholesterol efflux.
  • BCA activated PPARγ/LXRα and PPARγ/HO-1 pathways, inhibiting lipid accumulation and inflammation.

Conclusions:

  • Biochanin A demonstrates protective effects against atherosclerosis.
  • BCA inhibits lipid accumulation and inflammatory responses via PPARγ/LXRα and PPARγ/HO-1 signaling.
  • BCA presents a potential therapeutic agent for atherosclerotic cardiovascular disease prevention and treatment.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
On-Chip Endothelial Inflammatory Phenotyping12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

11.1K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89
Inflammation01:38

Inflammation

Overview
57.0K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
306
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
953
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
581